{"name":"Averitas Pharma, Inc.","slug":"averitas-pharma-inc","ticker":"","exchange":"","domain":"averitaspharma.com","description":"Averitas Pharma, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative pain management solutions. The company's lead product, Qutenza, is a capsaicin 8% topical system that has been approved for the treatment of neuropathic pain.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Capsaicin 8%","genericName":"Capsaicin 8%","slug":"capsaicin-8","indication":"Neuropathic pain (postherpetic neuralgia, peripheral neuropathy)","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"capsaicin 0.04% topical system","genericName":"capsaicin 0.04% topical system","slug":"capsaicin-0-04-topical-system","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Capsaicin 8%","genericName":"Capsaicin 8%","slug":"capsaicin-8","phase":"marketed","mechanism":"Capsaicin activates TRPV1 nociceptors on nerve fibers, causing initial stimulation followed by desensitization and depletion of substance P, resulting in reduced pain signaling.","indications":["Neuropathic pain (postherpetic neuralgia, peripheral neuropathy)","Localized musculoskeletal pain"],"catalyst":""},{"name":"capsaicin 0.04% topical system","genericName":"capsaicin 0.04% topical system","slug":"capsaicin-0-04-topical-system","phase":"phase_3","mechanism":"Capsaicin activates and then desensitizes TRPV1 receptors on sensory nerve endings, reducing pain signal transmission.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOT3lmRm9DV0ZDYzRUYUtLQXpra3RFRzA5UkVFNUIzSzg1VERmM2FhSllybDlZRVNjS3hnZjNVWlI0eklTdnFySm91RDBGRnRKRTZnY0Q4U1NxRkNYeEhqTHZOeDZZcjdaMEZTcDJXaGVKRmxzOHdLNzRRM0tiV3VhQ0xTclhYQVhhVWxyVGFxb2dPdmp6M09HdkxSUVY4ZEdFLUtkTzVydlkyTW9FRnc?oc=5","date":"2025-10-30","type":"pipeline","source":"Fortune","summary":"Championing a culture where purpose powers progress - Fortune","headline":"Championing a culture where purpose powers progress","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AJBVV95cUxPdGJBeU96MEg2dHVQQmFFcXEycnA4LUtpajM5U3hqSkdTdWo1X1lqVkF2QXNPeG9YOHU5VWlUWmFVdXZ5aGc4YTB1SWtoNmlDWDJqVEdMbWh0Y3hvR3ZLTlZEM3k1SXJjRjB2Mmt5OS1yUVI2NlB3Vk5WZFRKNlRiYW1QclFjUFFESklTb0tfQlgxNVAyclhSNWZEeGR1dUhla21sRGxlZTcyQXZwTWdRdDBUa0lMb0YzRDNFanQxM0tESTI4Tkt1ZUxsQXFFY29yclFjc3FTbEF2MkxjWUV3aHRydWl0Nks3VzNSeTl1YlFTeW5sYTAtRVZkcEI0dmU2dEpkamRxT212Smk4d2ppQ25pN3NTMjhHUV9pZkVxRERxLXdKMlBKei1yUGphZFJiWXdQSEN6ckpKRllpWlJoRWFJUUJWc19rUXVwamJHc1VwWmU0?oc=5","date":"2025-06-05","type":"pipeline","source":"Barchart.com","summary":"Diabetic Peripheral Neuropathy Market on Track for Major Expansion by 2034, According to DelveInsight | Grünenthal, Averitas Pharma, Daiichi Sankyo, Vertex Pharma, Helixmith, Lexicon Pharma, Glenmark ","headline":"Diabetic Peripheral Neuropathy Market on Track for Major Expansion by 2034, According to DelveInsight | Grünenthal, Aver","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTFBrcnU1MXhSRjhrbndsWEhvc0FhQWtZMnJZUFZDWENMSW96Mk0yN3BJZTRYRUpqTGRQV2psNzR2YkRqYzQ2MHdmS0NoRHdFNjFFWl92c1l6a1lZTWJvOVhhRmREblFpXzJxZEYtOERjS3dVZw?oc=5","date":"2024-11-08","type":"trial","source":"Clinical Trials Arena","summary":"Averitas completes recruitment for trial of QUTENZA to treat post-surgical pain - Clinical Trials Arena","headline":"Averitas completes recruitment for trial of QUTENZA to treat post-surgical pain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxPUWxLV3EwSnhhM04takdobGgwR3JtMXctd3Q0U25zZkJsSjFvcU5vdGo4RHZSX0hEUm9faGJVaTRxbXR2R1AzbksxQ3R2QVh4N28ydGFkTVYyNm9pWWgySjN0OFc2MHZ1THR2T1VpRTF4M3lSaGZGN2ZDQVhXRXdfMU5qTm9VN3RaOGU5M2tpSS1jZFhzQjRkOTBPWHZyWU10SlBHOGlBRjZOTFlBMURfcGhPRnVDOGdXeldUN0o3VUNGUjdGVlJTZ1VKWnRuYVU?oc=5","date":"2023-03-01","type":"pipeline","source":"sttinfo.fi","summary":"Janneke van der Kamp starts as new Chief Commercial Officer at Grünenthal. - sttinfo.fi","headline":"Janneke van der Kamp starts as new Chief Commercial Officer at Grünenthal.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxPc2ZuaDJYZUlBOVItY01LY2FqdFlFVnFCb3hqM0VramNlM1prZklnWGg2Q3cwMUJZWVFOWFZCUjBBMHJFYTNXeFdiNlZiTmRsVmE4dGs5MmgzSGZrZGQ4QmpoS1lpbEEwUjVXZF9GbDV6bHp5MVBIc0dpUkFUZzRPWkNqTUpMMm5pX3Rqam9hM3ZMT29mYzlSc3Eyd00wVjcxRXNzSTlYb1MzQjVieTZvSG1wU25pWF84VW12ZkxNdC1rTnREN0Y0Z0NfaDFueGps?oc=5","date":"2023-03-01","type":"pipeline","source":"Via TT","summary":"Janneke van der Kamp starts as new Chief Commercial Officer at Grünenthal - Via TT","headline":"Janneke van der Kamp starts as new Chief Commercial Officer at Grünenthal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNNW5ZRGIxaDktWEdWMU95ZDdnNUFQLXhtUVB5ZVdkR0xOMkd3NEVtRm9fRmhZWUV4YVZSUXFWOUtENGhlZVplb3Y4WVU4V1pmNVNjbmE4VDVzRENRMjUyUGlDa0k2bGQ3SlRsNVh1TUk2aGhNYXdYaEZTTGZpY3hmbzdwWVl2azk5Zm5JSzNxVjhQaGstOXQtUFJ3T1VFREV4SGZ5ak5LRjM?oc=5","date":"2022-05-25","type":"pipeline","source":"Diabetes Self-Management","summary":"Peripheral Neuropathy Description Contest Kicks Off - Diabetes Self-Management","headline":"Peripheral Neuropathy Description Contest Kicks Off - Diabetes Self","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQYmhBRFlCX0lQVWRoUFNEbm5veW5PeE1BMXdpVXVCaDN3UGltUWl6WEI3Y1BROUpZVGt2cTBrLVVXWjNvYWhrek1EblRwWW4zSlF1QkN3cThiWS1mRlZ5UjlDOGxOdnowLXc4QzdYcE9ZcE1qNWpUZVJIZVo0aWZfNQ?oc=5","date":"2022-05-04","type":"pipeline","source":"PR Newswire","summary":"SPEAK FOR YOUR FEET - PR Newswire","headline":"SPEAK FOR YOUR FEET","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxQeFloMFlNcTVtTHMzYnJWSE5zZWxTU04ya3ZUcGFIbVVDMmpYVnhjSzJzeVNsbWF1TTl4TktvbGhSRjFBMHNjcmtJVnNIUXZra2pzUTZBYzJrekRaUWRtRFplaUpmRmdXd2FLMUpfQlJTeWp1OEdJdzFOVG5yU0dqdW1oRXUyUjJjMThVYjdod1A1em5XNExyOVNHd2psQTBvU2JqdG1xR2E0ak5TOS0zT19KS05Pa3dLVC1MMWg0dkFWUzZVRldqVG1pVlo4MFRMeDRXLW1kNkNWUXo0T3VZX0g5d1B1ODFDa25OaU14bmNBVWM?oc=5","date":"2021-08-10","type":"trial","source":"Via Ritzau","summary":"First patient enrolled into a Phase III study with QUTENZA® in post-surgical neuropathic pain - Via Ritzau","headline":"First patient enrolled into a Phase III study with QUTENZA® in post-surgical neuropathic pain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPWUMzVnpwbGRvSWZ1TnlDcjZ4T18zVGVUM2xYU3lETzQ5X01mRXJUb2FSUEk1UWotRTRvSnBIc2tYV1FiU2xscEpaZnVxQ2dNQXpReTczRjBKbkRMbHRqLXhLMDFLNER0bHNJTTJwaXlPOUlzd3VHelRoWVJkaDl4V1lGRVZWR1BhS1NlZGU0SmJCaXp4aGVCVndpNGk5cmVYcFVUaUQ2RzFqZEYtYmVIb3pNVlhUVk41MnJsYlJTQlVWT3M?oc=5","date":"2021-04-12","type":"pipeline","source":"Fierce Pharma","summary":"Grünenthal's transformation: CEO Gabriel Baertschi about what's ahead for the global leader in pain management - Fierce Pharma","headline":"Grünenthal's transformation: CEO Gabriel Baertschi about what's ahead for the global leader in pain management","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxOWjNZbjdZbHd1TWhaWWFDNDlyNE5PdDRoQkdYV1NIZWNzbmtYaDRYUFg1azlsMGc5SWZtdTRRaVUxR096TjNhWi1zTER2U2ZTdjIzYVdTZ0wyS3k0WG1zdFJ5c19VOTNpT1BvNTJ4ZGdYdGZzYzNfT3AxSHFQLTI3aHJTcU1UY0t1aTdDcm5nWkZBYUNLUXM0anhzLTRlVGdwUlBnOG9qbGp5eG1XWlRiS01xWGlNLU1wWXlfUWRkYW10ZUhDT1hBRGdCbXlvTG14NHVYbTJhTTNua1k?oc=5","date":"2020-08-27","type":"pipeline","source":"11Alive.com","summary":"Diabetic Nerve Pain - 11Alive.com","headline":"Diabetic Nerve Pain - 11Alive.com","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE9ZUTNKOG1kclozaUE3TjFrZWxUbUsxYXdJRmx0VXhEelp6Q05RcllIUHBwalZxNFNRbk5Oa0V5SXhaYXB6TzhGMVdXYV93VWZmOXJoNjdjVWhPaXY3UG85WFoyaXBXM3JjRERDTg?oc=5","date":"2019-09-04","type":"regulatory","source":"Allied Market Research","summary":"Neuropathic Pain Market Size, Share, Trends & Demand [2032] - Allied Market Research","headline":"Neuropathic Pain Market Size, Share, Trends & Demand [2032]","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOWVpjbklWOUJTVFZjTTB6V3ZzVVlwWmYwSVk1anctWW5xUEFWODR0R056X004Z054X1lIRDZzYWpMSG5IdmNOTFMzLVpibDFkSFN0R29TVjVLZFU1RG5XVjl1LXNvWmpPMjhQUmpKdWRnVkpXU25uc2pvb1d2N3FWTV9BYk1DR2JHbU40X3V0Q0hRV1FZTkpKT1ZCelEzUEFUTTVpU2xNV0hCa2s0SmQ4?oc=5","date":"2018-11-14","type":"pipeline","source":"BioSpace","summary":"Grünenthal Snaps up Averitas Pharma for Undisclosed Sum to Extend Presence in the U.S. - BioSpace","headline":"Grünenthal Snaps up Averitas Pharma for Undisclosed Sum to Extend Presence in the U.S.","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":1,"phase_3":1},"enrichmentLevel":2,"visitCount":10,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}